Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM and Directorate Change

15 Dec 2023 14:07

RNS Number : 0306X
Frontier IP Group plc
15 December 2023
 

RNS

AIM: FIPP

15 December 2023

 

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Result of Annual General Meeting and Directorate Change

 

Frontier IP, a specialist in commercialising intellectual property, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed with the table below summarising proxy votes received.

The Company also confirms, as announced on 31 October 2023, that Andrew Richmond has not sought re-election as a director at today's annual general meeting and has stepped down from his role as Chairman with effect from today.

Dame Julia King, Baroness Brown of Cambridge has assumed the role of Chair following conclusion of today's AGM.

 

 RESOLUTIONS

NO OF VOTES FOR

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

NO OF VOTES AGAINST

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

TOTAL VOTES CAST (EXCLUDING VOTES WITHHELD)

NO OF VOTES WITHHELD

ORDINARY

1. To receive the audited consolidated financial statements of the Company and its subsidiaries for the year ended 30 June 2023, together with the reports of the Directors and the Auditor thereon.

28,798,831

100%

0

0%

28,798,831

7,001

2. To approve the report of the Board to the members on directors' remuneration for the year ended 30 June 2023.

24,016,521

83%

4,761,258

17%

28,777,779

28,053

3. To re-appoint Neil Crabb as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

3,000

0%

28,782,740

23,092

4. To re-appoint Jacqueline McKay as a Director of the Company and, being eligible, is offering herself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

5. To re-appoint James Fish as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

6. To re-appoint Matthew White as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

7. To re-appoint David Holbrook as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

8. To re-appoint Nigel Grierson as a Director of the Company and, being eligible, is offering himself for reappointment

28,779,740

100%

0

0%

28,779,740

26,092

9. To re-appoint Professor Dame Julia King, Baroness Brown of Cambridge as a Director of the Company and, being eligible, is offering herself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

10. To resolve not to fill the vacancy created by the retirement of Andrew Richmond as a Director and Chairman of the Company at the AGM, in accordance with the Articles of Association of the Company

28,801,720

100%

0

0%

28,801,720

4,001

11. To re-appoint BDO LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which financial statements are laid before shareholders.

28,797,617

100%

0

0%

28,797,617

8,215

12 To authorise the Directors to determine the auditor's remuneration

28,797,617

100%

4,214

0%

28,801,831

4,001

13. To authorise the directors to allot shares

28,779,740

100%

19,091

0%

28,798,831

7,001

SPECIAL

14. Authority to disapply pre-emption rights in connection with the allotment and issue of equity securities for cash in relation to (i) share option schemes; (ii) rights issue or similar offer; (iii) allotment of equity securities up to 10% of the issued share capital; or (iv) to the allotment of equity securities up to a nominal amount equal to 20%, such authority to be used only for the purposes of making a follow-on offer which the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights.

23,213,401

81%

5,585,430

19%

28,798,831

7,001

15. Authority to disapply pre-emption rights to allot equity securities for cash.

27,929,775

97%

849,965

3%

28,779,740

26,092

16. Authority to purchase own shares on market.

24,461,860

100%

7,850

0%

24,469,710

4,336,122

 

 

Votes which have been cast at the discretion of the Chairman have been counted as votes for the resolutions. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

 

M: 07464 546 025

andrew.johnson@frontierip.co.uk

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Harry Gooden / James Fischer

T: 0207 496 3000

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFFMFLIEDSESE
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.